Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Rafael Holdings Inc (RFL)

Rafael Holdings Inc (RFL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,320
  • Shares Outstanding, K 20,804
  • Annual Sales, $ 410 K
  • Annual Income, $ -124,660 K
  • 60-Month Beta 1.73
  • Price/Sales 96.92
  • Price/Cash Flow N/A
  • Price/Book 0.41
Trade RFL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.16
  • Most Recent Earnings -0.24 on 10/31/22
  • Next Earnings Date 12/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-6500 Real Estate

    Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 0.00% ( -97.40%)
  • Historical Volatility 46.10%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,465.09% on 09/14/22
  • IV Low 0.00% on 12/05/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 2,625
  • Open Int (30-Day) 2,490

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7200 +10.47%
on 11/08/22
2.0900 -9.09%
on 11/22/22
+0.0100 (+0.53%)
since 11/04/22
3-Month
1.6800 +13.10%
on 10/10/22
2.4100 -21.16%
on 09/14/22
-0.2100 (-9.95%)
since 09/02/22
52-Week
1.6000 +18.75%
on 05/12/22
6.4700 -70.63%
on 12/08/21
-3.4500 (-64.49%)
since 12/03/21

Most Recent Stories

More News
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.8801 (-0.52%)
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.8801 (-0.52%)
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.8801 (-0.52%)
Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics...

RFL : 1.8801 (-0.52%)
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.8801 (-0.52%)
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...

RFL : 1.8801 (-0.52%)
Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics...

RFL : 1.8801 (-0.52%)
William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

NEWARK, N.J., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), a company focused on discovering and developing novel cancer and...

RFL : 1.8801 (-0.52%)
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

CRANBURY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of...

RFL : 1.8801 (-0.52%)
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Company Will Open Additional Sites and Has Begun Enrolling Patients in the Second Cohort of the Trial...

RFL : 1.8801 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States.

See More

Key Turning Points

3rd Resistance Point 1.9900
2nd Resistance Point 1.9700
1st Resistance Point 1.9300
Last Price 1.8801
1st Support Level 1.8700
2nd Support Level 1.8500
3rd Support Level 1.8100

See More

52-Week High 6.4700
Fibonacci 61.8% 4.6097
Fibonacci 50% 4.0350
Fibonacci 38.2% 3.4603
Last Price 1.8801
52-Week Low 1.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar